The Sertraline Hydrochloride Tablet Market serves diverse psychiatric and neurological indications. Major depressive disorder represents the primary approved indication, with sertraline demonstrating efficacy across melancholic and atypical depression subtypes. The Sertraline Hydrochloride Tablet Market addresses obsessive-compulsive disorder with higher dosing requirements and longer treatment durations. Panic disorder management benefits from sertraline's anxiolytic properties without significant sedation. Post-traumatic stress disorder treatment shows particular efficacy for hyperarousal and intrusion symptoms. Social anxiety disorder responds well to sertraline's performance anxiety reduction. Premenstrual dysphoric disorder represents an important off-label application with significant patient impact. Combination therapy with atypical antipsychotics addresses treatment-resistant depression. Clinical positioning emphasizes sertraline's activation profile, gastrointestinal tolerability, and lower sedation compared to paroxetine.